Delayed diagnosis of Hyperinsulinism Hyperammonemia Syndrome: A case report

Can Thi Bich Ngoc, Nguyen Ngoc Khanh

Nội dung chính của bài viết

Tóm tắt

Hyperinsulinism Hyperammonemia Syndrome (HI/HA syndrome) is an autosomal dominant disease caused by activating mutations in GLUD1, the gene responsible for encoding the mitochondrial enzyme glutamate dehydrogenase (GDH). This syndrome represents the second most common genetic form of congenital hyperinsulinism in infancy. Children with HI/HA syndrome typically experience hypoglycemic symptoms triggered by fasting or high-protein meals and persistently elevated ammonia levels. We report a case of HI/HA syndrome in a 7-month-old female who presented with cyanosis and hyperammonemia, along with an initial normal glucose level at the time of presentation. About one week after the child’s admission to the hospital, we discovered that hypoglycemia was the cause of her irritability. The hypoglycemic episode was found to occur coincidentally with hyperammonemia. The combination of clinical findings, biochemical markers, and genetic sequencing identifying a GLUD1 pathogenic variant facilitated the correct diagnosis of HI/HA syndrome. As demonstrated by this case, the diagnosis of HI/HA syndrome requires a thorough clinical evaluation, comprehensive biochemical analysis, and genetic testing. With the correct diagnosis, a patient with HI/HA syndrome can receive ongoing monitoring and care with the goal of preventing adverse neurologic sequelae.
Hyperinsulinism Hyperammonemia Syndrome (HI/HA syndrome) is an autosomal dominant disease caused by activating mutations in GLUD1, the gene responsible for encoding the mitochondrial enzyme glutamate dehydrogenase (GDH). This syndrome represents the second most common genetic form of congenital hyperinsulinism in infancy. Children with HI/HA syndrome typically experience hypoglycemic symptoms triggered by fasting or high-protein meals and persistently elevated ammonia levels. We report a case of HI/HA syndrome in a 7-month-old female who presented cyanosis and hyperammonemia, along with an initial normal glucose level at the time of presentation. About one week after the child’s admission to the hospital, we discovered that hypoglycemia was the cause of her irritability. The hypoglycemic episode was found to occur coincidentally with hyperammonemia. The combination of clinical findings, biochemical markers, and genetic sequencing identifying a GLUD1 pathogenic variant facilitated the correct diagnosis of HI/HA syndrome.  As demonstrated by this case, the diagnosis of HI/HA syndrome requires a thorough clinical evaluation, comprehensive biochemical analysis, and genetic testing.  With the correct diagnosis, a patient with HI/HA syndrome can receive ongoing monitoring and care with the goal of preventing adverse neurologic sequelae

Chi tiết bài viết

Tài liệu tham khảo

1. Cochrane WA, Payne WW, Simpkiss MJ, et al. Familial hypoglycemia precipitated by amino acids. J Clin Invest. 1956;35(4):411-422. doi:10.1172/JCI103292
2. Andrea K, Andrew P. Charles AS. Congenital Hyperinsulinism Due to Activating Mutations of Glutamate Dehydrogenase: The Hyperinsulinism/Hyperammonemia Syndrome. Frontiers in Diabetes. 2012; 21:100-111. doi:10.1159/000334513
3. Stanley CA, Fang J, Kutyna K, et al. Molecular basis and characterization of the hyperinsulinism/hyperammonemia syndrome: predominance of mutations in exons 11 and 12 of the glutamate dehydrogenase gene. HI/HA Contributing Investigators. Diabetes. 2000;49(4):667-673. doi:10.2337/diabetes.49.4.667
4. Palladino AA, Stanley CA. The hyperinsulinism/hyperammonemia syndrome. Rev Endocr Metab Disord. 2010;11(3):171-178. doi:10.1007/s11154-010-9146-0
5. Plaitakis A, Kalef-Ezra E, Kotzamani D, et al. The Glutamate Dehydrogenase Pathway and Its Roles in Cell and Tissue Biology in Health and Disease. Biology (Basel). 2017;6(1):11. doi:10.3390/biology6010011
6. Arnoux JB, Verkarre V, Saint-Martin C, et al. Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J Rare Dis. 2011;6:63. doi:10.1186/1750-1172-6-63
7. Rosenfeld E, Nanga RPR, Lucas A, et al. Characterizing the neurological phenotype of the hyperinsulinism hyperammonemia syndrome. Orphanet J Rare Dis. 2022;17(1):248. doi:10.1186/s13023-022-02398-3
8. Bahi-Buisson N, Roze E, Dionisi C, et al. Neurological aspects of hyperinsulinism-hyperammonaemia syndrome. Dev Med Child Neurol. 2008;50(12):945-949. doi:10.1111/j.1469-8749.2008.03114.x
9. Hewat TI, Johnson MB, Flanagan SE. Congenital Hyperinsulinism: Current Laboratory-Based Approaches to the Genetic Diagnosis of a Heterogeneous Disease. Frontiers in Endocrinology. 2022;13. doi:10.3389/fendo.2022.873254
10. Yau D, Laver TW, Dastamani A, et al. Using referral rates for genetic testing to determine the incidence of a rare disease: The minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389. PLoS One. 2020;15(2):e0228417. doi:10.1371/journal.pone.0228417
11. Gao ZY, Li G, Najafi H, et al. Glucose regulation of glutaminolysis and its role in insulin secretion. Diabetes. 1999;48(8):1535-1542. doi:10.2337/diabetes.48.8.1535